Status:
TERMINATED
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Malignant Peripheral Nerve Sheath Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients ≥18 years of age
- Histologically documented diagnosis of malignant MPNST
- Unresectable local MPNST or metastatic MPNST and therefore incurable with any conventional multimodality approach Life expectancy of at least 6 months.
- Exclusion criteria:
- Patient has received any other investigational agents within 28 days of first day of study drug dosing.
- Chemotherapy and or radiotherapy in between the last 6 weeks before study entry, surgery in between the last 14 days before study entry.
- Female patients who are pregnant or breast feeding or women of child bearing potential who are not using a highly effective method of birth control.
- Known CNS metastases
- Other protocol-defined inclusion/exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00427583
Start Date
May 1 2006
Last Update
August 7 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Berlin, Germany
2
Novartis Investigative Site
Hamburg, Germany